Vascular extracellular matrix in atherosclerosis

Cardiology in Review

Volumn 21, Issue 6, 2013, Pages 270-288

  Chistiakov, Dimitry A ^a,b   Sobenin, Igor A ^b,c,d   Orekhov, Alexander N ^b,c  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b Institute for Atherosclerosis Research   (Russian Federation)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^d INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

atherosclerosis; extracellular matrix remodeling; macrophages; matrix metalloproteinases; vascular repair; vascular smooth muscle cells

Indexed keywords

BIOMATERIAL; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; NEUTROPHIL COLLAGENASE; PROTEIN INHIBITOR; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE SCAFFOLD;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CALCIFICATION; CARDIOVASCULAR RISK; ENGINEERING; EXTRACELLULAR MATRIX; IMAGING; INFLAMMATION; MACROPHAGE; NONHUMAN; PROTEIN FUNCTION; REVIEW; VASCULAR SURGERY; VASCULAR TISSUE;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE VIII; CYTOKINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; PLAQUE, ATHEROSCLEROTIC; T-LYMPHOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASES; VASCULAR CALCIFICATION;

EID: 84885648225     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31828c5ced     Document Type: Review

References (285)

1. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108-2114.
2. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:1281-1292.
3. Siasos G, Tousoulis D, Kioufis S, et al. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem. 2012;12:1132-1148.
4. Borkakoti N. Structural studies of matrix metalloproteinases. J Mol Med. 2000;78:261-268. (Pubitemid 30489710)
5. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA. 1990;87:5578-5582.
6. Murphy G, Knauper V, Atkinson S, et al. Cellular mechanisms for focal proteolysis and the regulation of the microenvironment. Fibrinolysis Proteolysis. 2000;14:165-174. (Pubitemid 30409289)
7. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
8. Leco KJ, Khokha R, Pavloff N, et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994; 269:9352-9360. (Pubitemid 24209266)
9. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-839. (Pubitemid 36542523)
10. van der Vorst EP, Keijbeck AA, de Winther MP, et al. A disintegrin and metalloproteases: molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis. 2012;224:302-308.
11. Bridges LC, Bowditch RD. ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity. Curr Pharm Des. 2005;11:837-847. (Pubitemid 40331034)
12. Yáñez-Mó M, Gutiérrez-López MD, Cabañas C. Functional interplay between tetraspanins and proteases. Cell Mol Life Sci. 2011;68:3323-3335.
13. Lu X, Lu D, Scully MF, et al. Structure-activity relationship studies on ADAM protein-integrin interactions. Cardiovasc Hematol Agents Med Chem. 2007;5:29-42. (Pubitemid 46062420)
14. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944-1949.
15. Pickering JG, Ford CM, Tang B, et al. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. Arterioscler Thromb Vasc Biol. 1997;17:475-482. (Pubitemid 27133136)
16. Bendeck MP, Nakada MT. The beta3 integrin antagonist m7E3 reduces matrix metalloproteinase activity and smooth muscle cell migration. J Vasc Res. 2001;38:590-599. (Pubitemid 33151599)
17. Ferri N, Carragher NO, Raines EW. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol. 2004;164:1575-1585. (Pubitemid 38529760)
18. Schönbeck U, Mach F, Sukhova GK, et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med. 1999;189:843-853. (Pubitemid 29189689)
19. Duivenvoorden WC, Hirte HW, Singh G. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 1999;17:27-34. (Pubitemid 29284561)
20. Nagase H. Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res. 1998;8:179-186. (Pubitemid 128544278)
21. Lim M, Martinez T, Jablons D, et al. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 1998;441:88-92. (Pubitemid 29012378)
22. Lijnen HR, Lupu F, Moons L, et al. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost. 1999;81:799-807. (Pubitemid 29216569)
23. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516. (Pubitemid 33096184)
24. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153:893-904. (Pubitemid 34289231)
25. Campbell JH, Campbell GR. The role of smooth muscle cells in atherosclerosis. Curr Opin Lipidol. 1994;5:323-330. (Pubitemid 24341341)
26. Smith EB. The influence of age and atherosclerosis on the chemistry of aortic intima.2. Collagen and mucopolysaccharides. J Atheroscler Res. 1965;5:241-248.
27. Siljander PR, Hamaia S, Peachey AR, et al. Integrin activation state determines selectivity for novel recognition sites in fibrillar collagens. J Biol Chem. 2004;279:47763-47772. (Pubitemid 39540925)
28. Leitinger B, Kwan AP. The discoidin domain receptor DDR2 is a receptor for type X collagen. Matrix Biol. 2006;25:355-364. (Pubitemid 44175833)
29. Konitsiotis AD, Raynal N, Bihan D, et al. Characterization of high affinity binding motifs for the discoidin domain receptor DDR2 in collagen. J Biol Chem. 2008;283:6861-6868.
30. Agarwal G, Mihai C, Iscru DF. Interaction of discoidin domain receptor 1 with collagen type 1. J Mol Biol. 2007;367:443-455. (Pubitemid 46295432)
31. Koyama H, Raines EW, Bornfeldt KE, et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 1996;87:1069-1078. (Pubitemid 26427990)
32. Li S, Lao J, Chen BPC, et al. Genomic analysis of smooth muscle cells in three-dimensional collagen matrix. FASEB J. 2003;17:97-99.
33. Liu B, Itoh H, Louie O, et al. The role of phospholipase C and phosphatidylinositol 3-kinase in vascular smooth muscle cell migration and proliferation. J Surg Res. 2004;120:256-265. (Pubitemid 38834194)
34. Hollenbeck ST, Itoh H, Louie O, et al. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the alpha2beta1 integrin and PDGFbeta receptor. Biochem Biophys Res Commun. 2004;325:328-337. (Pubitemid 39441197)
35. Sibinga NE, Foster LC, Hsieh CM, et al. Collagen VIII is expressed by vascular smooth muscle cells in response to vascular injury. Circ Res. 1997;80:532-541. (Pubitemid 27137290)
36. Plenz GA, Deng MC, Robenek H, et al. Vascular collagens: spotlight on the role of type VIII collagen in atherogenesis. Atherosclerosis. 2003;166:1-11. (Pubitemid 35449595)
37. Hou G, Mulholland D, Gronska MA, et al. Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury. Am J Pathol. 2000;156:467-476. (Pubitemid 30643802)
38. Adiguzel E, Hou G, Mulholland D, et al. Migration and growth are attenuated in vascular smooth muscle cells with type VIII collagen-null alleles. Arterioscler Thromb Vasc Biol. 2006;26:56-61. (Pubitemid 43732228)
39. Liu SQ, Teft BJ, Zhang LQ, et al. Elastic laminae in vascular development and disease. Mol Cell Biomech. 2010;7:59-76.
40. Hou G, Vogel W, Bendeck MP. The discoidin domain receptor tyrosine kinase DDR1 in arterial wound repair. J Clin Invest. 2001;107:727-735. (Pubitemid 32225358)
41. Hou G, Vogel WF, Bendeck MP. Tyrosine kinase activity of discoidin domain receptor 1 is necessary for smooth muscle cell migration and matrix metalloproteinase expression. Circ Res. 2002;90:1147-1149. (Pubitemid 34786897)
42. Franco C, Hou G, Ahmad PJ, et al. Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res. 2008;102:1202-1211.
43. Bendeck MP, Conte M, Zhang M, et al. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol. 2002;160:1089-1095. (Pubitemid 34224595)
44. Islam MM, Franco CD, Courtman DW, et al. A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. Am J Pathol. 2003;163:1557-1566. (Pubitemid 37175102)
45. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78:38-43. (Pubitemid 26004118)
46. Zempo N, Koyama N, Kenagy RD, et al. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28-33. (Pubitemid 26026928)
47. Serra P, Bruczko M, Zapico JM, et al. MMP-2 selectivity in hydroxamate-type inhibitors. Curr Med Chem. 2012;19:1036-1064.
48. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91:845-851. (Pubitemid 35285083)
49. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852-859. (Pubitemid 35285084)
50. Cheng L, Mantile G, Pauly R, et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 1998;98:2195-2201. (Pubitemid 28527480)
51. George SJ, Lloyd CT, Angelini GD, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation. 2000;101:296-304. (Pubitemid 30054157)
52. Kenagy RD, Vergel S, Mattsson E, et al. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 1996;16:1373-1382. (Pubitemid 26378228)
53. Assoian RK, Marcantonio EE. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest. 1996;98:2436-2439. (Pubitemid 26415061)
54. Bond M, Sala-Newby GB, Newby AC. Focal adhesion kinase (FAK)-dependent regulation of S-phase kinase-associated protein-2 (Skp-2) stability. A novel mechanism regulating smooth muscle cell proliferation. J Biol Chem. 2004;279:37304-37310. (Pubitemid 39195437)
55. Uglow EB, Slater S, Sala-Newby GB, et al. Dismantling of cadherin-mediated cell-cell contacts modulates smooth muscle cell proliferation. Circ Res. 2003;92:1314-1321. (Pubitemid 36773473)
56. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483-1487. (Pubitemid 38314410)
57. Skinner MP, Raines EW, Ross R. Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagencoated membranes. Am J Pathol. 1994;145:1070-1081.
58. Ichii T, Koyama H, Tanaka S, et al. Fibrillar collagen specifically regulates human vascular smooth muscle cell genes involved in cellular responses and the pericellular matrix environment. Circ Res. 2001;88:460-467. (Pubitemid 32240908)
59. Okada Y, Katsuda S, Matsui Y, et al. Collagen synthesis by cultured arterial smooth muscle cells during spontaneous phenotypic modulation. Acta Pathol Jpn. 1990;40:157-164. (Pubitemid 20210576)
60. Nelson PR, Yamamura S, Kent KC. Extracellular matrix proteins are potent agonists of human smooth muscle cell migration. J Vasc Surg. 1996;24:25-32; discussion 32.
61. Carragher NO, Levkau B, Ross R, et al. Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin. J Cell Biol. 1999;147:619-630.
62. Jones PL, Jones FS, Zhou B, et al. Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J Cell Sci. 1999;112 (pt 4):435-445. (Pubitemid 29106191)
63. Turner NJ, Murphy MO, Kielty CM, et al. Alpha2(VIII) collagen substrata enhance endothelial cell retention under acute shear stress flow via an alpha-2beta1 integrin-dependent mechanism: an in vitro and in vivo study. Circulation. 2006;114:820-829. (Pubitemid 44268232)
64. Baker AH, Zaltsman AB, George SJ, et al. Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998;101:1478-1487. (Pubitemid 28145266)
65. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol. 2004;24:54-60. (Pubitemid 38082411)
66. Mason DP, Kenagy RD, Hasenstab D, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res. 1999;85:1179-1185. (Pubitemid 30430623)
67. Aguilera CM, George SJ, Johnson JL, et al. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res. 2003;58:679-688. (Pubitemid 36694454)
68. Stringa E, Knäuper V, Murphy G, et al. Collagen degradation and plateletderived growth factor stimulate the migration of vascular smooth muscle cells. J Cell Sci. 2000;113 (pt 11):2055-2064. (Pubitemid 30386509)
69. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res. 2007;100:607-621. (Pubitemid 46594875)
70. Barillari G, Albonici L, Incerpi S, et al. Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function. Atherosclerosis. 2001;154:377-385. (Pubitemid 32146610)
71. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189. (Pubitemid 24187750)
72. Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and-12 in IL-13-induced inflammation and remodeling. J Clin Invest. 2002;110:463-474. (Pubitemid 34919700)
73. Galis ZS, Muszynski M, Sukhova GK, et al. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci. 1995;748:501-507.
74. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165-197.
75. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994. (Pubitemid 43732102)
76. Wesley RB 2nd, Meng X, Godin D, et al. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol. 1998;18:432-440. (Pubitemid 28125638)
77. Gudewicz PW, Frewin MB, Heinel LA, et al. Priming of human monocyte superoxide production and arachidonic acid metabolism by adherence to collagen-and basement membrane-coated surfaces. J Leukoc Biol. 1994;55:423-429. (Pubitemid 24122517)
78. Kisslov L, Hadad N, Rosengraten M, et al. HT-29 human colon cancer cell proliferation is regulated by cytosolic phospholipase A(2)? dependent PGE(2)via both PKA and PKB pathways. Biochim Biophys Acta. 2012;1821:1224-1234.
79. Ghesquiere SA, Gijbels MJ, Anthonsen M, et al. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J Lipid Res. 2005;46:201-210. (Pubitemid 40271083)
80. Andreeva ER, Pugach IM, Orekhov AN. Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta. Atherosclerosis. 1997;130:133-142. (Pubitemid 27191033)
81. Lepidi S, Kenagy RD, Raines EW, et al. MMP9 production by human monocyte-derived macrophages is decreased on polymerized type I collagen. J Vasc Surg. 2001;34:1111-1118. (Pubitemid 33660675)
82. Shapiro SD, Kobayashi DK, Pentland AP, et al. Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme-and substrate-specific responses involving prostaglandin-dependent mechanisms. J Biol Chem. 1993;268:8170-8175. (Pubitemid 23120402)
83. Schapira K, Lutgens E, de Fougerolles A, et al. Genetic deletion or antibody blockade of alpha1beta1 integrin induces a stable plaque phenotype in ApoE-/-mice. Arterioscler Thromb Vasc Biol. 2005;25:1917-1924. (Pubitemid 41243463)
84. Grenache DG, Coleman T, Semenkovich CF, et al. Alpha2beta1 integrin and development of atherosclerosis in a mouse model: assessment of risk. Arterioscler Thromb Vasc Biol. 2003;23:2104-2109. (Pubitemid 37433207)
85. Galt SW, Lindemann S, Medd D, et al. Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circ Res. 2001;89:509-516. (Pubitemid 34132645)
86. Gowen BB, Borg TK, Ghaffar A, et al. The collagenous domain of class A scavenger receptors is involved in macrophage adhesion to collagens. J Leukoc Biol. 2001;69:575-582. (Pubitemid 32294842)
87. Kamohara H, Yamashiro S, Galligan C, et al. Discoidin domain receptor 1 isoform-a (DDR1alpha) promotes migration of leukocytes in three-dimensional collagen lattices. FASEB J. 2001;15:2724-2726.
88. Matsuyama W, Wang L, Farrar WL, et al. Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: role of p38 mitogen-activated protein kinase and NFkappa B. J Immunol. 2004;172:2332-2340. (Pubitemid 38182381)
89. Abdulhussein R, McFadden C, Fuentes-Prior P, et al. Exploring the collagen-binding site of the DDR1 tyrosine kinase receptor. J Biol Chem. 2004;279:31462-31470. (Pubitemid 39037814)
90. Franco C, Britto K, Wong E, et al. Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis. Circ Res. 2009;105:1141-1148.
91. Franco C, Ahmad PJ, Hou G, et al. Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1. Circ Res. 2010;106:1775-1783.
92. Savion N, Zavaro O, Kotev-Emeth S. Oxidation decreases low density lipoprotein association with the subendothelium extracellular matrix. Biochem Biophys Res Commun. 1998;245:497-501. (Pubitemid 28418533)
93. Dunér P, To F, Alm R, et al. Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease. J Intern Med. 2009;265:593-603.
94. Dunér P, To F, Beckmann K, et al. Immunization of apoE-/-mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis. Cardiovasc Res. 2011;91:528-536.
95. Cheong C, Choi JH. Dendritic cells and regulatory T cells in atherosclerosis. Mol Cells. 2012;34:341-347.
96. Dunér P, To F, Berg K, et al. Immune responses against aldehyde-modified laminin accelerate atherosclerosis in Apoe-/-mice. Atherosclerosis. 2010;212:457-465.
97. Caligiuri G, Rossignol P, Julia P, et al. Reduced immunoregulatory CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2006;26:618-623.
98. Ferrari-Lacraz S, Nicod LP, Chicheportiche R, et al. Human lung tissue macrophages, but not alveolar macrophages, express matrix metalloproteinases after direct contact with activated T lymphocytes. Am J Respir Cell Mol Biol. 2001;24:442-451. (Pubitemid 32324733)
99. Dobaczewski M, Xia Y, Bujak M, et al. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol. 2010;176:2177-2187.
100. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol. 2011;162:1453-1469.
101. Corti R, Hutter R, Badimon JJ, et al. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis. 2004;17:35-44. (Pubitemid 39069460)
102. Knäuper V, López-Otin C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem. 1996;271:1544-1550. (Pubitemid 26028643)
103. Williams KE, Olsen DR. Matrix metalloproteinase-1 cleavage site recognition and binding in full-length human type III collagen. Matrix Biol. 2009;28:373-379.
104. Rekhter MD, Hicks GW, Brammer DW, et al. Hypercholesterolemia causes mechanical weakening of rabbit atheroma: local collagen loss as a prerequisite of plaque rupture. Circ Res. 2000;86:101-108. (Pubitemid 30044174)
105. Malik N, Greenfield BW, Wahl AF, et al. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 1996;156:3952-3960. (Pubitemid 26139945)
106. Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol. 1998;152:199-207. (Pubitemid 28028060)
107. Lacraz S, Dayer JM, Nicod L, et al. 1,25-dihydroxyvitamin D3 dissociates production of interstitial collagenase and 92-kDa gelatinase in human mononuclear phagocytes. J Biol Chem. 1994;269:6485-6490.
108. Whatling C, Björk H, Gredmark S, et al. Effect of macrophage differentiation and exposure to mildly oxidized LDL on the proteolytic repertoire of THP-1 monocytes. J Lipid Res. 2004;45:1768-1776. (Pubitemid 39296217)
109. Rajavashisth TB, Xu XP, Jovinge S, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation. 1999;99:3103-3109. (Pubitemid 29289074)
110. Sukhova GK, Schönbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503-2509. (Pubitemid 29228279)
111. Shankavaram UT, Lai WC, Netzel-Arnett S, et al. Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem. 2001;276:19027-19032.
112. Khan KM, Howe LR, Falcone DJ. Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. J Biol Chem. 2004;279:22039-22046. (Pubitemid 38679395)
113. Corcoran ML, Kibbey MC, Kleinman HK, et al. Laminin SIKVAV peptide induction of monocyte/macrophage prostaglandin E2 and matrix metalloproteinases. J Biol Chem. 1995;270:10365-10368.
114. Pavlovic S, Du B, Sakamoto K, et al. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem. 2006;281:3321-3328. (Pubitemid 43852881)
115. Cipollone F, Fazia ML, Iezzi A, et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol. 2005;25:1925-1931. (Pubitemid 41243464)
116. Chase AJ, Bond M, Crook MF, et al. Role of nuclear factor-kappa B activation in metalloproteinase-1,-3, and-9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol. 2002;22:765-771. (Pubitemid 34517787)
117. Park JY, Park JH, Jang W, et al. Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases. J Biochem. 2012;151:291-298.
118. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003;126(pt 12):2738-2749. (Pubitemid 37463092)
119. Nold M, Goede A, Eberhardt W, et al. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:68-75. (Pubitemid 36207683)
120. Matías-Román S, Gálvez BG, Genís L, et al. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood. 2005;105:3956-3964. (Pubitemid 40656143)
121. Johnson JL, Baker AH, Oka K, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation. 2006;113:2435-2444. (Pubitemid 43948051)
122. Shipley JM, Wesselschmidt RL, Kobayashi DK, et al. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA. 1996;93:3942-3946. (Pubitemid 26144227)
123. Sithu SD, English WR, Olson P, et al. Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem. 2007;282:25010-25019. (Pubitemid 47347548)
124. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest. 1990;86:1496-1502. (Pubitemid 20372596)
125. Ardans JA, Economou AP, Martinson JM Jr, et al. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and-9 by activated monocytes. J Leukoc Biol. 2002;71:1012-1018.
126. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104:1899-1904. (Pubitemid 32983231)
127. Zhou M, Zhang Y, Ardans JA, et al. Interferon-gamma differentially regulates monocyte matrix metalloproteinase-1 and-9 through tumor necrosis factoralpha and caspase 8. J Biol Chem. 2003;278:45406-45413. (Pubitemid 37432678)
128. Castrillo A, Joseph SB, Marathe C, et al. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem. 2003;278:10443-10449. (Pubitemid 36800310)
129. Gibbs DF, Warner RL, Weiss SJ, et al. Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol. 1999;20:1136-1144. (Pubitemid 129503231)
130. Oviedo-Orta E, Bermudez-Fajardo A, Karanam S, et al. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology. 2008;124:42-50. (Pubitemid 351537571)
131. Mach F, Schönbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-399. (Pubitemid 27329409)
132. Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation. 2002;106:3024-3030. (Pubitemid 35440283)
133. Johnson JL, Sala-Newby GB, Ismail Y, et al. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1647-1653.
134. Kuzuya M, Nakamura K, Sasaki T, et al. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:1120-1125. (Pubitemid 43732121)
135. Lessner SM, Martinson DE, Galis ZS. Compensatory vascular remodeling during atherosclerotic lesion growth depends on matrix metalloproteinase-9 activity. Arterioscler Thromb Vasc Biol. 2004;24:2123-2129. (Pubitemid 39482440)
136. Choi ET, Collins ET, Marine LA, et al. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1020-1025. (Pubitemid 40627849)
137. Johnson JL, George SJ, Newby AC, et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA. 2005;102:15575-15580. (Pubitemid 41528098)
138. Johnson JL, Devel L, Czarny B, et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2011;31:528-535.
139. Dwivedi A, Slater SC, George SJ. MMP-9 and-12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res. 2009;81:178-186.
140. Lyon CA, Johnson JL, Williams H, et al. Soluble N-cadherin overexpression reduces features of atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2009;29:195-201.
141. Deguchi JO, Aikawa E, Libby P, et al. Matrix metalloproteinase-13/ collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation. 2005;112:2708-2715. (Pubitemid 41532609)
142. Fukumoto Y, Deguchi JO, Libby P, et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation. 2004;110:1953-1959. (Pubitemid 39331907)
143. Schneider F, Sukhova GK, Aikawa M, et al. Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation. 2008;117:931-939. (Pubitemid 351272591)
144. Shimokawa H. Bone-marrow-derived matrix metalloproteinase-14: a novel target for plaque stability. Circulation. 2008;117:863-865. (Pubitemid 351272583)
145. Lemaître V, Kim HE, Forney-Prescott M, et al. Transgenic expression of matrix metalloproteinase-9 modulates collagen deposition in a mouse model of atherosclerosis. Atherosclerosis. 2009;205:107-112.
146. Silence J, Lupu F, Collen D, et al. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:1440-1445. (Pubitemid 34219805)
147. Lemaître V, O'Byrne TK, Borczuk AC, et al. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest. 2001;107:1227-1234. (Pubitemid 32494539)
148. Lemaître V, Soloway PD, D'Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation. 2003;107:333-338. (Pubitemid 36135233)
149. Cuaz-Pérolin C, Jguirim I, Larigauderie G, et al. Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development. J Vasc Res. 2006;43:493-501. (Pubitemid 44691401)
150. Rouis M, Adamy C, Duverger N, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation. 1999;100:533-540. (Pubitemid 29360163)
151. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res. 2002;90:897-903. (Pubitemid 34633882)
152. Eagleton MJ, Ballard N, Lynch E, et al. Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during angiotensin II induced aneurysm formation. J Surg Res. 2006;135:345-351. (Pubitemid 44414882)
153. Wang TL, Yang YH, Chang H, et al. Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol. 2004;37:785-794. (Pubitemid 39194570)
154. Hernandez-Barrantes S, Toth M, Bernardo MM, et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem. 2000;275:12080-12089. (Pubitemid 30237783)
155. Liang J, Liu E, Yu Y, et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation. 2006;113:1993-2001.
156. Matsumoto S, Kobayashi T, Katoh M, et al. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am J Pathol. 1998;153:109-119. (Pubitemid 28317513)
157. Gadeau AP, Chaulet H, Daret D, et al. Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury. J Histochem Cytochem. 2001;49:79-86. (Pubitemid 32012843)
158. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis. 2008;199:271-277.
159. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006;99:1044-1059. (Pubitemid 44729928)
160. Tintut Y, Patel J, Territo M, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105:650-655. (Pubitemid 34123443)
161. Gössl M, Mödder UI, Atkinson EJ, et al. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol. 2008;52:1314-1325.
162. Gössl M, Mödder UI, Gulati R, et al. Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. Eur Heart J. 2010;31:2909-2914.
163. Doehring LC, Heeger C, Aherrahrou Z, et al. Myeloid CD34+CD13+ precursor cells transdifferentiate into chondrocyte-like cells in atherosclerotic intimal calcification. Am J Pathol. 2010;177:473-480.
164. Boström K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809. (Pubitemid 23127387)
165. Bobryshev YV. Transdifferentiation of smooth muscle cells into chondrocytes in atherosclerotic arteries in situ: implications for diffuse intimal calcification. J Pathol. 2005;205:641-650. (Pubitemid 40514838)
166. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104:733-741.
167. Boström KI, Jumabay M, Matveyenko A, et al. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 2011;108:446-457.
168. Suga T, Iso T, Shimizu T, et al. Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb. 2011;18:670-683.
169. Ting TC, Miyazaki-Anzai S, Masuda M, et al. Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells. J Biol Chem. 2011;286:23938-23949.
170. Giachelli CM, Bae N, Almeida M, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696. (Pubitemid 23304531)
171. MacBeath JR, Kielty CM, Shuttleworth CA. Type VIII collagen is a product of vascular smooth-muscle cells in development and disease. Biochem J. 1996;319 (pt 3):993-998. (Pubitemid 26386219)
172. Tintut Y, Alfonso Z, Saini T, et al. Multilineage potential of cells from the artery wall. Circulation. 2003;108:2505-2510. (Pubitemid 37444413)
173. Ding HT, Wang CG, Zhang TL, et al. Fibronectin enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells via ERK pathway. J Cell Biochem. 2006;99:1343-1352.
174. Basalyga DM, Simionescu DT, Xiong W, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation. 2004;110:3480-3487. (Pubitemid 39602227)
175. Fischer JW, Steitz SA, Johnson PY, et al. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004;24:2391-2396. (Pubitemid 39658047)
176. Aigner T, Neureiter D, Câmpean V, et al. Expression of cartilage-specific markers in calcified and non-calcified atherosclerotic lesions. Atherosclerosis. 2008;196:37-41.
177. Watson KE, Parhami F, Shin V, et al. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol. 1998;18:1964-1971. (Pubitemid 28565761)
178. Severson AR, Ingram RT, Fitzpatrick LA. Matrix proteins associated with bone calcification are present in human vascular smooth muscle cells grown in vitro. In Vitro Cell Dev Biol Anim. 1995;31:853-857. (Pubitemid 26020405)
179. Li SW, Prockop DJ, Helminen H, et al. Transgenic mice with targeted inactivation of the Col2 alpha 1 gene for collagen II develop a skeleton with membranous and periosteal bone but no endochondral bone. Genes Dev. 1995;9:2821-2830.
180. Qiao JH, Fishbein MC, Demer LL, et al. Genetic determination of cartilaginous metaplasia in mouse aorta. Arterioscler Thromb Vasc Biol. 1995;15:2265-2272. (Pubitemid 26001430)
181. Ahmad PJ, Trcka D, Xue S, et al. Discoidin domain receptor-1 deficiency attenuates atherosclerotic calcification and smooth muscle cell-mediated mineralization. Am J Pathol. 2009;175:2686-2696.
182. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857-2867. (Pubitemid 41103395)
183. Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep. 2003;5:222-226.
184. Bobryshev YV, Killingsworth MC, Huynh TG, et al. Are calcifying matrix vesicles in atherosclerotic lesions of cellular origin? Basic Res Cardiol. 2007;102:133-143. (Pubitemid 46189954)
185. Hsu HH, Camacho NP, Sun F, et al. Isolation of calcifiable vesicles from aortas of rabbits fed with high cholesterol diets. Atherosclerosis. 2000;153:337-348. (Pubitemid 32120332)
186. Kapustin AN, Davies JD, Reynolds JL, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res. 2011;109:e1-e12.
187. Chen NX, O'Neill KD, Chen X, et al. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res. 2008;23:1798-1805.
188. Kumata C, Mizobuchi M, Ogata H, et al. Involvement of matrix metalloproteinase-2 in the development of medial layer vascular calcification in uremic rats. Ther Apher Dial. 2011;15(suppl 1):18-22.
189. Hosaka N, Mizobuchi M, Ogata H, et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int. 2009;85:523-529.
190. Xu L, Peng H, Wu D, et al. Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with osteoarthritis in mice. J Biol Chem. 2005;280:548-555. (Pubitemid 40165020)
191. Tchetina EV, Kobayashi M, Yasuda T, et al. Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis. Matrix Biol. 2007;26:247-258. (Pubitemid 46660592)
192. Wu CW, Tchetina EV, Mwale F, et al. Proteolysis involving matrix metalloproteinase 13 (collagenase-3) is required for chondrocyte differentiation that is associated with matrix mineralization. J Bone Miner Res. 2002;17:639-651. (Pubitemid 34246639)
193. Li ZY, Howarth S, Tang T, et al. Does calcium deposition play a role in the stability of atheroma? Location may be the key. Cerebrovasc Dis. 2007;24:452-459. (Pubitemid 350014971)
194. Wong KK, Thavornpattanapong P, Cheung SC, et al. Effect of calcification on the mechanical stability of plaque based on a three-dimensional carotid bifurcation model. BMC Cardiovasc Disord. 2012;12:7.
195. Wahlgren CM, Zheng W, Shaalan W, et al. Human carotid plaque calcification and vulnerability. Relationship between degree of plaque calcification, fibrous cap inflammatory gene expression and symptomatology. Cerebrovasc Dis. 2009;27:193-200.
196. Xu X, Ju H, Cai J, et al. High-resolution MR study of the relationship between superficial calcification and the stability of carotid atherosclerotic plaque. Int J Cardiovasc Imaging. 2010;26(suppl 1):143-150.
197. Fitzgerald PJ, Ports TA, Yock PG. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation. 1992;86:64-70.
198. Bobryshev YV, Killingsworth MC, Lord RS, et al. Matrix vesicles in the fibrous cap of atherosclerotic plaque: possible contribution to plaque rupture. J Cell Mol Med. 2008;12(5B):2073-2082.
199. Bobryshev YV, Killingsworth MC, Orekhov AN. Increased shedding of microvesicles from intimal smooth muscle cells in athero-prone areas of the human aorta: implications for understanding of the predisease stage. Pathobiology. 2013;80:24-31.
200. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287-5297.
201. Romero JR, Vasan RS, Beiser AS, et al. Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring Study. J Stroke Cerebrovasc Dis. 2008;17:412-417.
202. Tayebjee MH, Nadar S, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004;17:764-769. (Pubitemid 39201090)
203. Hansson J, Vasan RS, Ärnlöv J, et al. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS ONE. 2011;6:e16185.
204. Ehrlich JR, Kaluzny M, Baumann S, et al. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol. 2011;100:1029-1036.
205. Sundström J, Vasan RS. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol. 2006;17:45-53. (Pubitemid 43100302)
206. Cavusoglu E, Ruwende C, Chopra V, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J. 2006;151:1101.e1- 1101.e8.
207. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med. 2003;51:295-300. (Pubitemid 37210891)
208. Gostiljac D, Dor?evi? PB, Djuri? D, et al. The importance of defining serum MMP-9 concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome. Acta Physiol Hung. 2011;98:91-97.
209. Orbe J, Montero I, Rodríguez JA, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J Thromb Haemost. 2007;5:91-97. (Pubitemid 44921072)
210. Wilson EM, Gunasinghe HR, Coker ML, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002;8:390-398. (Pubitemid 36055741)
211. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089-2096.
212. Barascuk N, Vassiliadis E, Zheng Q, et al. Levels of circulating MMCN-151, a degradation product of mimecan, reflect pathological extracellular matrix remodeling in apolipoprotein E knockout mice. Biomark Insights. 2011;6:97-106.
213. Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43:899-904.
214. Jefferis BJ, Whincup P, Welsh P, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis. 2010;208:557-563.
215. Lenglet S, Thomas A, Chaurand P, et al. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. Thromb Haemost. 2012;107:409-416.
216. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001;7:743-748. (Pubitemid 32588033)
217. Wagner S, Breyholz HJ, Faust A, et al. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem. 2006;13:2819-2838. (Pubitemid 44509727)
218. Breyholz HJ, Wagner S, Levkau B, et al. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q J Nucl Med Mol Imaging. 2007;51:24-32. (Pubitemid 46824659)
219. Wagner S, Breyholz HJ, Law MP, et al. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2®-[[(4-methoxyphenyl)sulfonyl]( benzyl)-and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J Med Chem. 2007;50:5752-5764. (Pubitemid 350106030)
220. Faust A, Waschkau B, Waldeck J, et al. Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix metalloproteinases. Bioconjug Chem. 2008;19:1001-1008. (Pubitemid 351748307)
221. Schäfers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2004;109:2554-2559. (Pubitemid 38720556)
222. Fujimoto S, Hartung D, Ohshima S, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol. 2008;52:1847-1857.
223. Ouimet T, Lancelot E, Hyafil F, et al. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging. Mol Pharm. 2012;9:850-861.
224. Hu J, Van den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6:480-498. (Pubitemid 47064570)
225. Dormán G, Cseh S, Hajdú I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs. 2010;70:949-964.
226. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2006;69:677-687. (Pubitemid 43139730)
227. Hajduk PJ, Shuker SB, Nettesheim DG, et al. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J Med Chem. 2002;45:5628-5639. (Pubitemid 35453755)
228. Takahashi K, Ikura M, Habashita H, et al. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach. Bioorg Med Chem. 2005;13:4527-4543. (Pubitemid 40813241)
229. Grams F, Brandstetter H, D'Alò S, et al. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol Chem. 2001;382:1277-1285. (Pubitemid 32894035)
230. Agrawal A, Romero-Perez D, Jacobsen JA, et al. Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem. 2008;3:812-820.
231. Lagente V, Boichot E. Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol. 2010;48: 440-444.
232. Engel CK, Pirard B, Schimanski S, et al. Structural basis for the highly selective inhibition of MMP-13. Chem Biol. 2005;12:181-189. (Pubitemid 40281325)
233. Devy L, Dransfield DT. New strategies for the next generation of matrixmetalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem Res Int. 2011;2011:191670.
234. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69:1517-1526.
235. Franco C, Ho B, Mulholland D, et al. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am J Pathol. 2006;168:1697-1709.
236. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265. (Pubitemid 43144395)
237. Dodd BR, Spence RA. Doxycycline inhibition of abdominal aortic aneurysm growth: a systematic review of the literature. Curr Vasc Pharmacol. 2011;9:471-478.
238. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57-63.
239. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-775. (Pubitemid 36566165)
240. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer. 2010;126:239-246.
241. Rubino MT, Agamennone M, Campestre C, et al. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem. 2011;6:1258-1268.
242. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:283-288. (Pubitemid 36231941)
243. Reel B, Sala-Newby GB, Huang WC, et al. Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes. Br J Pharmacol. 2011;163:1679-1690.
244. Johnston SS, Bell K, Gdovin J, et al. Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption. Hosp Pract (Minneap). 2012;40:15-23.
245. Berger PB, Alderman EL, Nadel A, et al. Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass. Circulation. 1999;100:2353-2358.
246. Kannan RY, Salacinski HJ, Butler PE, et al. Current status of prosthetic bypass grafts: a review. J Biomed Mater Res Part B Appl Biomater. 2005;74:570-581. (Pubitemid 40917728)
247. Conte MS. The ideal small arterial substitute: a search for the Holy Grail? FASEB J. 1998;12:43-45.
248. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev. 2009;89:957-989.
249. Dahl SL, Koh J, Prabhakar V, et al. Decellularized native and engineered arterial scaffolds for transplantation. Cell Transplant. 2003;12:659-666. (Pubitemid 37204423)
250. Conklin BS, Wu H, Lin PH, et al. Basic fibroblast growth factor coating and endothelial cell seeding of a decellularized heparin-coated vascular graft. Artif Organs. 2004;28:668-675. (Pubitemid 38858450)
251. Cho SW, Lim SH, Kim IK, et al. Small-diameter blood vessels engineered with bone marrow-derived cells. Ann Surg. 2005;241:506-515. (Pubitemid 40299729)
252. DiMuzio P, Fischer L, McIlhenny S, et al. Development of a tissue-engineered bypass graft seeded with stem cells. Vascular. 2006;14:338-342. (Pubitemid 46579400)
253. Dong JD, Huang JH, Gao F, et al. Mesenchymal stem cell-based tissue engineering of small-diameter blood vessels. Vascular. 2011;19:206-213.
254. Heise RL, Ivanova J, Parekh A, et al. Generating elastin-rich small intestinal submucosa-based smooth muscle constructs utilizing exogenous growth factors and cyclic mechanical stimulation. Tissue Eng Part A. 2009;15:3951-3960.
255. Robotin-Johnson MC, Swanson PE, Johnson DC, et al. An experimental model of small intestinal submucosa as a growing vascular graft. J Thorac Cardiovasc Surg. 1998;116:805-811. (Pubitemid 28499175)
256. Marshall SE, Tweedt SM, Greene CH, et al. An alternative to synthetic aortic grafts using jejunum. J Invest Surg. 2000;13:333-341. (Pubitemid 32046811)
257. Sekine H, Shimizu T, Yang J, et al. Pulsatile myocardial tubes fabricated with cell sheet engineering. Circulation. 2006;114(1 suppl):I87-I93. (Pubitemid 44297134)
258. Sekiya S, Muraoka M, Sasagawa T, et al. Three-dimensional cell-dense constructs containing endothelial cell-networks are an effective tool for in vivo and in vitro vascular biology research. Microvasc Res. 2010;80:549-551.
259. Ottani V, Raspanti M, Ruggeri A. Collagen structure and functional implications. Micron. 2001;32:251-260.
260. Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissueequivalents. Matrix Biol. 2003;22:339-350. (Pubitemid 36993759)
261. Weinberg CB, Bell E. A blood vessel model constructed from collagen and cultured vascular cells. Science. 1986;231:397-400. (Pubitemid 16108649)
262. Habermehl J, Skopinska J, Boccafoschi F, et al. Preparation of ready-to-use, stockable and reconstituted collagen. Macromol Biosci. 2005;5:821-828. (Pubitemid 41360880)
263. Charulatha V, Rajaram A. Influence of different crosslinking treatments on the physical properties of collagen membranes. Biomaterials. 2003;24:759-767. (Pubitemid 35449828)
264. Orban JM, Wilson LB, Kofroth JA, et al. Crosslinking of collagen gels by transglutaminase. J Biomed Mater Res A. 2004;68:756-762. (Pubitemid 38263940)
265. Brinkman WT, Nagapudi K, Thomas BS, et al. Photo-cross-linking of type I collagen gels in the presence of smooth muscle cells: mechanical properties, cell viability, and function. Biomacromolecules. 2003;4:890-895. (Pubitemid 36939454)
266. Nerem RM, Ensley AE. The tissue engineering of blood vessels and the heart. Am J Transplant. 2004;4 (suppl 6):36-42. (Pubitemid 38282277)
267. Feng Z, Matsumoto T, Nakamura T. Measurements of the mechanical properties of contracted collagen gels populated with rat fibroblasts or cardiomyocytes. J Artif Organs. 2003;6:192-196. (Pubitemid 37229241)
268. Baguneid M, Murray D, Salacinski HJ, et al. Shear-stress preconditioning and tissue-engineering-based paradigms for generating arterial substitutes. Biotechnol Appl Biochem. 2004;39(pt 2):151-157. (Pubitemid 38510060)
269. Ye Q, Zünd G, Benedikt P, et al. Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering. Eur J Cardiothorac Surg. 2000;17:587-591. (Pubitemid 30256271)
270. Clark RA. Fibrin glue for wound repair: facts and fancy. Thromb Haemost. 2003;90:1003-1006. (Pubitemid 38004417)
271. Jockenhoevel S, Zund G, Hoerstrup SP, et al. Fibrin gel-advantages of a new scaffold in cardiovascular tissue engineering. Eur J Cardiothorac Surg. 2001;19:424-430. (Pubitemid 32297774)
272. Grassl ED, Oegema TR, Tranquillo RT. A fibrin-based arterial media equivalent. J Biomed Mater Res A. 2003;66:550-561. (Pubitemid 37517200)
273. Lillie MA, Gosline JM. The viscoelastic basis for the tensile strength of elastin. Int J Biol Macromol. 2002;30:119-127. (Pubitemid 34242691)
274. Isenberg BC, Tranquillo RT. Long-term cyclic distention enhances the mechanical properties of collagen-based media-equivalents. Ann Biomed Eng. 2003;31:937-949.
275. Ramamurthi A, Vesely I. Evaluation of the matrix-synthesis potential of crosslinked hyaluronan gels for tissue engineering of aortic heart valves. Biomaterials. 2005;26:999-1010. (Pubitemid 39208986)
276. Daamen WF, Hafmans T, Veerkamp JH, et al. Comparison of five procedures for the purification of insoluble elastin. Biomaterials. 2001;22:1997-2005. (Pubitemid 32567636)
277. Buijtenhuijs P, Buttafoco L, Poot AA, et al. Tissue engineering of blood vessels: characterization of smooth-muscle cells for culturing on collagen-andelastin-based scaffolds. Biotechnol Appl Biochem. 2004;39(pt 2):141-149. (Pubitemid 38510059)
278. Nagapudi K, Brinkman WT, Thomas BS, et al. Viscoelastic and mechanical behavior of recombinant protein elastomers. Biomaterials. 2005;26:4695-4706. (Pubitemid 40343018)
279. Owen SC, Shoichet MS. Design of three-dimensional biomimetic scaffolds. J Biomed Mater Res A. 2010;94:1321-1331.
280. Urry DW. Five axioms for the functional design of peptide-based polymers as molecular machines and materials: principles for macromolecular assembly. Biopolymers. 1998;47:167-178.
281. Nagarsekar A, Crissman J, Crissman M, et al. Genetic engineering of stimulisensitive silkelastin-like protein block copolymers. Biomacromolecules. 2003;4:602-607. (Pubitemid 36701229)
282. Shekaran A, Garcia AJ. Nanoscale engineering of extracellular matrixmimetic bioadhesive surfaces and implants for tissue engineering. Biochim Biophys Acta. 2011;1810:350-360.
283. de Mel A, Bolvin C, Edirisinghe M, et al. Development of cardiovascular bypass grafts: endothelialization and applications of nanotechnology. Expert Rev Cardiovasc Ther. 2008;6:1259-1277.
284. Chan G, Mooney DJ. New materials for tissue engineering: towards greater control over the biological response. Trends Biotechnol. 2008;26:382-392.
285. Pradhan S, Farach-Carson MC. Mining the extracellular matrix for tissue engineering applications. Regen Med. 2010;5:961-970.